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Abstract
Amyloid is deposited in the walls of arteries and capillaries as
cerebral amyloid angiopathy (CAA) in the brains of older individuals
and of those with Alzheimer disease (AD). CAA in AD reflects an
age-related failure of elimination of amyloid-beta (Aβ) from the brain
along perivascular lymphatic drainage pathways. In the absence of
conventional lymphatic vessel in the brain, interstitial fluid and
solutes drain from the brain to cervical lymph nodes along narrow
basement membranes in the walls of capillaries and arteries, a
pathway that is largely separate from the cerebrospinal fluid. In this
review we focus on the pathology and pathogenesis of CAA, its
role in the aetiology of AD and its impact on immunotherapy for
AD. The motive force for lymphatic drainage of the brain appears to
be generated by arterial pulsations. Failure of elimination of Aβ
along perivascular pathways coincides with a reduction in enzymic
degradation of Aβ, reduced absorption of Aβ into the blood and
age-related stiffening of artery walls that appears to reduce the
motive force for lymphatic drainage. Reduced clearances of Aβ
and CAA are associated with the accumulation of insoluble and
soluble Aβs in the brain in AD and the probable loss of
homeostasis of the neuronal environment due to retention of
soluble metabolites within the brain. Tau metabolism may also be
affected. Immunotherapy has been successful in removing
insoluble plaques of Aβ from the brain in AD but with little effect on
cognitive decline. One major problem is the increase in CAA in
immunised patients that probably prevents the complete removal of
Aβ from the brain. Increased knowledge of the physiology and
structural and genetic aspects of the lymphatic drainage of Aβ
from the brain will stimulate the development of therapeutic
strategies for the prevention and treatment of AD.
Introduction
Deposition of amyloid-beta (Aβ) in the walls of cerebral
arteries and capillaries as cerebral amyloid angiopathy (CAA)
has a prevalence of 90% to 96% in patients with Alzheimer
disease (AD) [1] and is present in 30% of non-demented
individuals over the age of 60 years [2]. CAA reflects an age-
related failure of elimination of Aβ from the brain along
perivascular lymphatic drainage pathways by which interstitial
fluid (ISF) and solutes drain from the brain [3-5]. This failure
may be a key factor in the aetiology of AD.
Most organs have networks of lymphatic vessels that
transport fluid, protein macromolecules, cells and particulate
matter from tissue to lymph nodes. Lymphatic drainage along
these vessels relies upon highly competent valves, an
extrinsic pump action generated by external forces from
surrounding tissues and an intrinsic pump generated by
coordinated contractions of lymphatic muscle cells [6]. There
are no conventional lymphatics in the brain. Instead, ISF and
solutes drain out of the brain along narrow basement
membranes in the walls of capillaries and arteries to lymph
nodes in the neck [3,7], probably driven by an intrinsic pump
powered by vascular pulsations [8]. The perivascular
lymphatic drainage pathway for ISF and solutes from the
brain is largely separate from the cerebrospinal fluid (CSF)
[7,9]. With increasing age, the brain, with its almost unique
lymphatic drainage system, develops problems with lymphatic
drainage of Aβ and other amyloids and these problems are
rarely seen in other organs. As a result, soluble and insoluble
Aβs accumulate in vessel walls and in brain parenchyma.
CAA in AD is a protein-elimination-failure arteriopathy (PEFA)
[5,7] common to other forms of CAA in which a variety of
amyloidogenic peptides accumulate in the walls of cerebral
arteries. Non-Aβ forms of CAA tend to be hereditary in origin
and are associated with intracerebral haemorrhage or
dementia [10]. Mutated cystatin C is deposited in the walls of
cerebral arteries as CAA and occasionally in arteries
elsewhere in the body in the autosomal dominant hereditary
cerebral haemorrhage with amyloidosis of Icelandic type
(HCHWA-1) [10,11]. Patients suffer intracerebral haemor-
rhage at an early age, and those who survive may develop
dementia [11]. Variant transthyretin accumulates in vessels in
Review
Cerebral amyloid angiopathy in the aetiology and
immunotherapy of Alzheimer disease
Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare
Clinical Neurosciences, University of Southampton School of Medicine, LD74, South Laboratory & Pathology Block, Southampton General Hospital,
Southampton, SO16 6YD, UK
Corresponding author: Roy O Weller, row@soton.ac.uk
Published: 13 October 2009 Alzheimer’s Research & Therapy 2009, 1:6 (doi:10.1186/alzrt6)
This article is online at http://alzres.com/content/1/2/6
© 2009 BioMed Central Ltd
Aβ = amyloid-beta; AD = Alzheimer disease; ApoE = apolipoprotein E; CAA = cerebral amyloid angiopathy; CSF = cerebrospinal fluid; ISF = inter-
stitial fluid; LRP-1 = lipoprotein receptor-related protein-1; NFT = neurofibrillary tangle; PrP = prion protein.Alzheimer’s Research & Therapy    Vol 1 No 2 Weller et al.
Page 2 of 13
(page number not for citation purposes)
the endoneurium of peripheral nerves in familial amyloid
peripheral neuropathy [12], and in some families, there is
deposition of mutant transthyretin in the walls of leptomenin-
geal arteries and in brain parenchyma [10]. In the Finnish type
of familial amyloidosis, systemic and cerebral amyloidosis is
related to the protein gesolin [10]. Two of the most carefully
documented forms of hereditary CAA are those related to the
British and Danish forms of familial dementia [10]. Mutations
in the BRI2 gene are associated with deposition of ABri and
ADan amyloids in brain and spinal cord and as CAA [10].
BRI2 mRNA and BRI2 protein are widely expressed by
neurons and glia but are not expressed by cerebrovascular
smooth muscle cells [13], suggesting that the amyloid in the
vessel walls is derived from the brain rather than produced
locally by smooth muscle cells in the artery walls. Prion
proteins (PrPs) are deposited mainly in brain parenchyma in
human and animal prion disorders such as Creutzfeldt-Jacob
disease, scrapie and bovine spongiform encephalopathy [14].
However, PrP CAA has been reported in familial and sporadic
human disease [10] and in certain types of scrapie in which
there is a truncated form of PrP [15], suggesting that PrP may
normally drain from the brain along perivascular pathways.
In this review, we concentrate on Aβ-CAA as it is the
commonest type of CAA and has a very significant
association with intracerebral haemorrhage and dementia in
the older population [16]. In particular, we focus on the
pathology, pathogenesis and complications of CAA, its
relationship to the aetiology of AD and how it affects the
clinical outcome of immunotherapy for AD. Many of the
general principles that have emerged from the study of Aβ-
CAA can be applied to the other, less common, types of CAA
[10]. As Aβ acts as a natural tracer for the drainage of solutes
from the human brain, CAA has been a useful model for
establishing lymphatic drainage pathways of the human brain
and their significance for neuroimmunology [7,17].
Pathology of cerebral amyloid angiopathy
The first detailed descriptions of CAA are attributed to Scholz
[18], who described the deposition of proteinaceous material
within cerebral artery and capillary walls and as excrescences
or Drusen on the outer aspects of vessels in the brain
(drusige Entartung). In the 1980s, it was from leptomeningeal
arteries with CAA that Glenner and colleagues [19] first
isolated and characterised Aβ.
The distribution of CAA in the different regions of the brain
corresponds to the distribution of plaques of Aβ [20-22]. In
AD, plaques and CAA both appear to follow a sequence
involving the cerebral isocortex (neocortex) at the earliest
stages, then the allocortex of the hippocampus and related
structures, followed by involvement of the basal ganglia and
thalamus [20-22]. The structures of the walls of arteries in the
neocortex and basal ganglia differ [23] and this may partly
account for the less frequent deposition of Aβ as plaques and
CAA in the basal ganglia [20,22,23].
The shorter and more soluble Aβ40 is most abundant in CAA,
whereas the longer and less soluble Aβ42 predominates in
Aβ plaques within brain parenchyma [23]. Apolipoprotein E
(ApoE) co-localises with Aβ, both in plaques in the brain and
with Aβ in the walls of capillaries and arteries in CAA [22,23].
Together with age, APOE ε4 genotype is a major risk factor
for both CAA and AD [1].
Cerebral amyloid angiopathy in leptomeningeal arteries
Leptomeningeal arteries on the surface of the cerebral
hemispheres are most commonly affected by CAA, arteries in
the cerebral cortex are less affected, and capillaries are even
less frequently involved by CAA. Medium-sized lepto-
meningeal arteries often have a patchy deposition of Aβ in the
media or in the adventitia on the outer aspects of the artery
wall (Figure 1a) [23]. Small arteries may show dense
accumulation of Aβ in the tunica media (Figure 1a), or as
seen in an artery entering the cerebral cortex in Figure 1b,
there may be a reticular pattern of Aβ deposition that reflects
the accumulation of Aβ in the basement membranes of the
smooth muscle cells in the tunica media [4,5,24].
Aβ is detectable by thioflavin staining or by immunohisto-
chemistry mainly in the walls of leptomeningeal arteries with a
diameter of less than 60 μm [4], but this reveals only part of
the picture. Biochemical investigations have detected Aβ in
intracranial vessels as large as the basilar and middle
cerebral arteries in individuals as young as 20 years of age
(the youngest tested) and increasing sharply in those from 50
to 70 years of age [25]. Aβ was undetectable in the walls of
extracranial blood vessels [25]. In transgenic mouse models
of Aβ-CAA, there is heavy deposition of Aβ in the walls of
leptomeningeal arteries, but involvement may start with the
larger arteries at the base of the brain [26]. Veins do not
appear to be involved in CAA, although deposits of Aβ are
found attached to the walls of veins when CAA of
leptomeningeal arteries is severe; this may be due to flakes of
amyloid detaching from artery walls in the subarachnoid
space and attaching to veins [23].
Cerebral amyloid angiopathy in cortical arteries
Aβ may be deposited in the whole or part of the circumference
of the wall of cortical arteries (Figure 2a). When arteries are
viewed in a longitudinal plane, however, deposition of amyloid
is often discontinuous along the length of the vessel
(Figure 2b). Transverse bands (Figure 2c) reflect the depo-
sition of amyloid in basement membranes surrounding smooth
muscle cells in the tunica media [4]. A similar patchy
distribution is seen in the walls of leptomeningeal arteries
[4,27]. The discontinuous nature of the amyloid deposits in
CAA means that estimating the true incidence and severity of
CAA is probably most accurately performed on isolated
cerebral vessels rather than on sections of brain [27].
Aβ is frequently deposited in the glia limitans that surrounds
arteries in the cortex. However, it is unlikely that Aβ drainsdirectly from the glia limitans into the artery wall [28] as the
adjacent artery wall may lack Aβ (Figure 2d), and in the less
severely involved vessels, there is discontinuity across the
artefactual space [28] that separates Aβ in the artery wall
from deposits in the glia limitans (Figure 2d-f). ApoE is also
deposited in the glia limitans and co-localises with the Aβ
[22]. The ligand in the glia limitans to which the Aβ binds is
not known and it may be that Aβ is taken up by astrocytes
[22]. Dystrophic neurites are also seen in the perivascular glia
limitans, although again the reason is not clear [1]. At the
surface of the cerebral cortex, deposition of Aβ may be seen
in the glia limitans remote from artery walls [4] (Figure 2f),
which suggests that the deposits are due to an inherent
property of the glia limitans rather than related to perivascular
drainage of Aβ.
Deposition of Aβ in basement membranes in artery walls
appears to impair the perivascular drainage of ISF and
solutes from the brain [3,5], but it has other effects. Smooth
muscle cells are lost from artery walls in CAA and replaced
by amyloid (Figure 2g,h), and the affected vessels may show
severe degenerative changes that are associated with
cerebral haemorrhage [29].
Capillary amyloid angiopathy
Deposits of Aβ in capillary walls are much less common than
Aβ deposits in the walls of cortical and leptomeningeal
arteries [30]. Capillary CAA is seen mostly in areas that are
devoid of Aβ plaques [31,32], and the Aβ in the capillary
walls is mainly Aβ42 [30].
Capillaries with no Aβ in their walls may be closely asso-
ciated with diffuse plaques of Aβ (Figure 3a). In CAA,
insoluble Aβ is deposited in the basement membranes of
capillary endothelia (Figure 3b-d) and as excrescences or
Drusen (Figure 3c-h) that are smooth and globular
(Figure 3c,d,f), irregular (Figure 3e) or filamentous (Figure 3g,h).
Drusen are continuous with Aβ in the capillary basement
membrane. Both types of pericapillary deposit of Aβ can be
demonstrated in paraffin sections (Figure 3c-e), in smear
preparations of brain [28] (Figure 3f-h) or on vessels isolated
by digesting away the surrounding brain tissue [4]. The
consolidated globular Drusen (Figure 3c,d,f ) may be older
than the filamentous deposits of Aβ where the strands of
amyloid are in the extracellular spaces of the brain
parenchyma through which solutes diffuse to reach the
drainage pathways in the capillary walls [3,33].
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Figure 1
Cerebral amyloid angiopathy in Alzheimer disease. (a) Small leptomeningeal arteries (SLAs) on the surface of the cerebral cortex show dense
deposits of amyloid-beta (Aβ) in their walls, whereas the medium-sized arteries (MLAs) show a more dispersed pattern of deposition of Aβ. 
A cortical artery with cerebral amyloid angiopathy (CxA) is surrounded by plaques of Aβ in the brain parenchyma (pan-Aβ immunohistochemistry).
(b) Branch of a leptomeningeal artery entering the cerebral cortex. Amyloid (red) is in the basement membranes (as outlined by collagen IV staining
[5]) surrounding smooth muscle cells [4] (dark spaces) in the tunica media (confocal microscopy of Congo red stained preparation). Scale bars =
100 μm (a) and 50 μm (b).Alzheimer’s Research & Therapy    Vol 1 No 2 Weller et al.
Page 4 of 13
(page number not for citation purposes)
Figure 2
Cerebral amyloid angiopathy: amyloid-beta (Aβ) in cortical and leptomeningeal artery walls. (a) Cortical artery with deposition of Aβ in its wall but
with no Aβ in the glia limitans (pan-Aβ immunohistochemistry). Smear preparations of cortical arteries showing (b) a patchy transverse banding
pattern of amyloid deposition with no amyloid deposits attached to the outer aspect of the artery and (c) transverse banding of amyloid associated
with the basement membranes of smooth muscle cells [4,5] (thioflavin S stain: confocal images). Pan-Aβ immunohistochemistry of cortical arteries
showing (d) Aβ in the glia limitans but with no Aβ in the vessel wall, (e) deposits of Aβ in the artery wall and in the glia limitans but no continuity
between the two Aβ deposits and (f) Aβ in an artery wall with a heavy deposit of Aβ in the glia limitans both surrounding the vessel and on the
surface of the brain (top). There is no continuity between the staining in the vessel wall and the glia limitans. A cored amyloid plaque in the brain
parenchyma is seen to the left of the artery. Leptomeningeal arteries showing (g) deposition of Aβ in the vessel walls (pan-Aβ
immunohistochemistry) and (h) loss of alpha-smooth muscle actin staining in the artery walls in relation to the deposition of Aβ; arteries in (h) are
the same as those in (g). (Immunohistochemistry for alpha-smooth muscle actin.) Scale bars = 20 μm (a-e,g,h) and 50 μm (f). Reprinted with
permission from John Wiley & Sons, Inc. [28].Available online http://alzres.com/content/1/2/6
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Figure 3
Capillary amyloid angiopathy. Pan-amyloid-beta (pan-Aβ) immunohistochemistry. (a) A diffuse plaque of Aβ in cerebral cortex with a capillary,
devoid of Aβ, running through it. Cortical capillaries are surrounded by (b) a thin layer of Aβ corresponding to the perivascular basement membrane
(c) with attached globular deposits of Aβ (Drusen) continuous with Aβ in the capillary wall. (d) Globular Aβ Drusen partly surround the capillary
wall. Confocal images were stained with thioflavin S. (e) Histological section of a cortical capillary with a spiky Druse of amyloid continuous with
amyloid in the capillary wall. (f) Smear preparations of multiple globular Drusen and (g) filiform deposits of amyloid attached to cortical capillaries
whose walls also stain for amyloid. (h) Higher magnification shows continuity of the filaments with amyloid in the capillary wall. Scale bars = 20 μm
(a-d,f-h) and 10 μm (e). Reprinted with permission from John Wiley & Sons, Inc. [28].Pathogenesis of cerebral amyloid angiopathy
Early theories for the pathogenesis of CAA suggested that
the Aβ in vessel walls was derived from the blood [18,19] or
from vascular smooth muscle cells [24]. However, transgenic
mouse lines that overexpress human Aβ only in neurons in the
brain develop CAA [34], suggesting that Aβ is probably not
derived from the blood in CAA but from the brain [5].
Furthermore, Aβ is deposited not only in the walls of arteries
in CAA but also in the walls of capillaries that lack smooth
muscle [34,35]. Although smooth muscle cells in artery walls
produce Aβ (in common with most cells in the body) and may
contribute to CAA, they do not appear to be the main source
of Aβ in CAA [5,36]. In BRI2-related dementia [13], ABri
amyloid is not produced by vascular smooth muscle cells, yet
CAA is a very prominent pathological feature; this again
suggests that amyloid in CAA is derived from the central
nervous system. Most of the evidence now points to the
failure of perivascular lymphatic drainage of Aβ as a major
factor in the pathogenesis of CAA in AD [5,23].
Failure of perivascular lymphatic drainage of amyloid-
beta from the brain
Perivascular lymphatic drainage pathways by which ISF and
solutes drain from the brain have been defined in
experimental animals [3,9,37], and Aβ is deposited in those
pathways in CAA as its drainage fails with age (Figure 4).
Fluorescent tracers injected into the striatum of the mouse
brain initially spread diffusely through the brain parenchyma,
but within 5 minutes, the tracers are located in the capillary
basement membranes and in the basement membranes
around smooth muscle cells in the tunica media of arteries
[3]. Tracers are taken up in small amounts by vascular
smooth muscle cells and by perivascular macrophages along
the lymphatic drainage route [3]. Lymphatic drainage of ISF
along artery walls appears to be almost completely separate
from CSF [7]. Only 15% of radioactive tracer injected into the
ISF is recoverable from the CSF, and the majority of tracer
drains to the cervical lymph nodes [9] at a rate equivalent to
lymphatic drainage from other tissues [9]. Radioactive tracers
injected into the brain were located in the adventitia of
intracranial arteries but were absent from the walls of the
carotid artery in the neck [9]. This suggests that solutes
draining from the brain pass along the walls of intracranial
arteries but leave the carotid artery wall at the base of the
skull en route to the cervical lymph nodes [7,9].
Figure 4 summarises the major mechanisms and routes for
the elimination of Aβ from the brain. Observations from tracer
studies and from CAA (Figures 1-3) suggest that, as Aβ
leaves the brain, it initially diffuses with ISF and other solutes
through the narrow and tortuous extracellular spaces of the
grey matter [3,33,38] (Figure 4). It then enters the bulk
drainage pathways in the 100- to 150-nm-thick endothelial
basement membranes in the walls of capillaries [3,28,33] to
drain out of the brain along basement membranes in the
tunica media of cortical and leptomeningeal arteries [5].
Basement membranes of the arterial endothelium are not
involved in the drainage of fluorescent tracers and do not
contain stainable Aβ in CAA [3,5] (Figure 4). This may be one
reason why CAA in older patients and in those with AD is not
accompanied by catastrophic arterial thrombosis. Although
capillaries may be occluded and reduced in number in AD
[39], thrombotic occlusion of arteries in AD is not as wide-
spread as CAA.
Tracer studies suggest that fluid and solutes move to the
adventitia of leptomeningeal arteries and from there to the
lymph nodes at the base of the skull [7,9]. In CAA, Aβ is
detected by immunohistochemistry mainly in the tunica media
of smaller leptomeningeal arteries but is present in the
adventitia on the outer aspects of medium-sized leptomenin-
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Figure 4
Elimination of amyloid-beta (Aβ) from the brain. Aβ is (i) produced by
neurons and other cells in the brain and then (ii) diffuses with
interstitial fluid and other solutes through the narrow extracellular
spaces (ECS) of the brain to (iii) the bulk flow lymphatic drainage
pathways in the basement membranes of capillaries and in the tunica
media of artery walls and (iv) out of the brain to cervical lymph nodes.
Smooth muscle cells and perivascular macrophages take up Aβ and
are part of the elimination pathway. Degradation of Aβ occurs in the
brain parenchyma, by neprilysin and other enzymes, and Aβ is
absorbed into the blood by LRP-1 (lipoprotein receptor-related protein-
1)-mediated mechanisms in capillary endothelia. These mechanisms
for the elimination of Aβ from the brain tend to fail with age and in
Alzheimer disease.geal arteries [23], suggesting that Aβ follows the same
lymphatic drainage route as tracers in experimental animals
[7,9]. Restriction of Aβ to the walls of intracranial arteries and
its absence from the walls of the extracranial carotid artery
[25] suggest that Aβ drains from the wall of the carotid artery
to lymph nodes related to the artery at the base of the skull
[40]. The pattern of deposition of Aβ in the basement
membranes of capillary and artery walls in CAA indicates that
there is a failure of lymphatic drainage of Aβ and suggests
that the failure is related to age changes in artery walls.
Age changes in cerebral arteries and the aetiology of
cerebral amyloid angiopathy
As arteries age, fibrous tissue increases in the tunica intima
and tunica media (arteriosclerosis and arteriolosclerosis) and
arteries become stiffer [23]. Such age changes may interfere
with the motive force for transport of ISF and solutes, like
soluble Aβ, out of the brain. Theoretical models suggest that
the contrary (reflection) wave that follows the pulse wave in
arteries is the motive force that drives ISF and solutes out of
the brain along perivascular pathways in the direction
opposite to the flow of blood in the lumen [8]. Stretching of
the basement membrane with expansion of the artery during
systole may be the valve that prevents reflux during the
subsequent pulse wave [23]. If the pulse wave is the motive
force for perivascular drainage of Aβ, then stiffening of artery
walls with age may interfere with that force.
Vascular basement membrane changes that occur with age
and defects in innervation of cerebral vessel may also play
roles in the pathogenesis of CAA [8,23]. Overproduction of
transforming growth factor-beta-1 in transgenic mice results
in changes in vascular basement membranes and induces
CAA [41]. Furthermore, experimental cholinergic deafferen-
tation of arteries within the brain, induced by the destruction
of the nucleus basalis, results in CAA that resolves with re-
innervation [42]. These observations emphasise the need to
view the lymphatic drainage pathways as a dynamic entity in
the context of the whole neurovascular unit [43].
Pathogenesis of cerebral amyloid angiopathy in
capillaries
Capillary CAA is much less common than CAA in
leptomeningeal or cortical arteries and has been associated
with severe dementia [44] and with APOE ε4 genotype [31].
However, this does not explain the pathogenesis of capillary
CAA. An association between capillary CAA and thrombotic
occlusion of cortical arteries has been reported [32], and
there is an increase in capillary CAA in the brains of patients
treated with immunotherapy [45]. In both of these instances,
capillary CAA is associated with a paucity or absence of Aβ
plaques in the surrounding brain parenchyma and the
deposition of Aβ in capillary walls. In the immunised patients
with AD, there is an increase in Aβ42 in the walls of blood
vessels, suggesting that it is derived from plaque Aβ [46]. It
seems that the removal of Aβ from plaques by microglia,
activated by either ischaemia or immunisation, results in an
overload of the drainage pathways in capillary walls by which
Aβ drains from the brain.
Failure of other mechanisms for elimination of amyloid-
beta aggravates cerebral amyloid angiopathy
Arranged along the pathway for the drainage of soluble Aβ
from the brain is an array of enzymes and mechanisms for the
elimination of Aβ (Figure 4) [1]. Enzymes that degrade Aβ are
present in the brain parenchyma and in artery walls [1].
Mechanisms that mediate absorption of Aβ into the blood via
capillary endothelium or uptake of Aβ by smooth muscle cells
are also present in the walls of cerebral blood vessels [1].
Neprilysin, angiotensin-converting enzyme and insulin-
degrading enzyme are among the Aβ-degrading enzymes to
which Aβ is exposed as it diffuses through the extracellular
spaces of grey matter in the brain and along the perivascular
drainage pathways [1]. Neprilysin can hydrolyse monomeric
and oligomeric forms of Aβ40 and Aβ42. However, abnormal
forms of Aβ that result from the Flemish, Dutch, Italian and
Arctic mutations in the APP gene are not cleaved by
neprilysin and these familial disorders are associated with
severe CAA and early-onset cerebral haemorrhage or dementia
[10]. Neprilysin is produced by pyramidal neurons and by
smooth muscle cells in the walls of arteries [47]; a reduction
of neprilysin in artery walls is associated with severe CAA in
AD and in transgenic mice [47,48]. Other enzymes that
degrade Aβ in the walls of cerebral arteries are also deficient
or less active in AD [1].
Absorption of Aβ into the blood, mediated by low-density lipo-
protein receptor-related protein-1 (LRP-1) located in capillary
endothelium [43,49], is a major mechanism for elimination of
Aβ from the brain [43] and is six times faster than lymphatic
drainage [50]. LRP-1 also mediates the entry of Aβ into
vascular smooth muscle cells, where it is degraded [43].
Failure of LRP-1-related elimination of Aβ with age [49] or in
conditions of hypoxia [43] may also increase the flow of soluble
Aβ into perivascular drainage pathways already compromised
by age changes in the artery walls themselves [23].
There is evidence that the perivascular macrophages that
take up tracer draining along perivascular pathways [3] also
degrade Aβ [51]. In APP transgenic mice that overproduce
human Aβ, stimulation of perivascular macrophages reduces
the severity of CAA whereas depletion of these cells
increases the severity of CAA [51]. Enzymic and absorptive
mechanisms appear to fail with age [1]. Such a failure may be
a factor that aggravates CAA in older patients and in those
with AD by diverting more Aβ into the ageing perivascular
drainage pathways [23].
Complications of cerebral amyloid angiopathy
The major complications associated with CAA are (a) rupture
of amyloid-laden arteries, resulting in acute and often fatal
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tion of lymphatic drainage of ISF and solutes along artery
walls; and (d) cerebral hypoperfusion. The last two complica-
tions apply particularly to AD. Intracerebral haemorrhage is a
feature of familial and sporadic CAA [52]. Familial cases of
Aβ-CAA typically present with recurrent cerebral haemor-
rhages, white matter lesions and cognitive impairment 20 years
earlier than patients with sporadic CAA [52]. Mutant Aβ in
some forms of familial CAA is resistant to degradation by
neprilysin and thus may increase the amount of Aβ draining
along perivascular pathways [52]. In sporadic CAA-related
haemorrhage, the temporal and occipital lobes are
preferentially affected [53], and although the major risk factor
for the development of CAA is the APOE ε4 allele, the ε2 allele
predisposes to haemorrhage [29]. Artery walls often show
severe degenerative changes in addition to severe CAA [29].
Aβ-related angiitis is a complication of CAA [52,54]. Patients
present at a mean age of 67 years with changes in mental
status, headaches, seizures, focal neurological signs or
hallucinations [54]. The angiopathy may be granulomatous with
accumulation of lymphocytes around leptomeningeal arteries
and the presence of multinucleated giant cells in vessel walls
related to deposits of Aβ. There is microglial activation in the
cortex and white matter hyperintensities on magnetic
resonance imaging [54]. The presence of angiitis in relation to
CAA may have implications for immunotherapy in AD [52,54].
Cerebral amyloid angiopathy in the aetiology
of Alzheimer disease
CAA affects two of the major functions of cerebral arteries in
AD: (a) the blood supply to the brain and (b) the lymphatic
drainage of ISF and solutes from the brain. Accumulation of
Aβ and the loss of smooth muscle cells in CAA result in
decreased vascular reactivity to functional stimulation and
affect the blood supply to the brain in AD [16,43,55].
Pathologically, CAA initially affects the leptomeningeal and
parenchymal arteries of the cerebral cortex whereas severe
arteriosclerosis tends to affect the vessels in the basal
ganglia in the initial stages, and both are associated with
defects in blood flow and cognitive decline in AD [20].
Accumulation of amyloid-beta in the brain in Alzheimer
disease
Figure 5 summarises the role of impaired lymphatic drainage
of the brain and CAA in the accumulation of Aβ in the brain in
AD. Diffusion of Aβ through the extracellular spaces of the
brain and along the drainage pathways in artery walls [56,57]
is impaired by plaques of Aβ in the brain [58,59]. CAA also
restricts the drainage of Aβ along perivascular pathways as
seen in tg2576 transgenic mice in which plasma levels of Aβ
fall and levels of Aβ in the brain rise as CAA develops [60].
There is evidence that the failure of elimination of Aβ and fluid
from the brain correlates with CAA in human AD. First, severe
CAA correlates with severe dementia [61]. Second, high
levels of soluble Aβ40 in brain parenchyma, with up to a
threefold increase, distinguish demented patients with AD
from non-demented patients, even though the non-demented
patients may have high numbers of insoluble Aβ plaques in
their brains [62]. Third, accumulation of fluid in cerebral white
matter (leukoaraiosis) in AD has been correlated with the
severity of CAA [27], suggesting that Aβ in artery walls may
block the perivascular drainage of fluid and solutes from
white matter as well as from grey matter.
These observations suggest that one of the main patho-
genetic roles of insoluble Aβ is to block the elimination of fluid
and solutes from the brain. This may result in the
accumulation of toxic soluble fibrillar oligomers of Aβ in the
brain in AD [63]. But it may equally well result in the
accumulation of other soluble metabolites and the loss of
homeostasis of the neuronal environment with consequent
impairment of neuronal function.
Variability of cerebral amyloid angiopathy in Alzheimer
disease
The reported prevalence of CAA in histological studies of
brains of patients with AD varies from 90% to 96% [1].
However, the true prevalence of CAA in AD may be
significantly underestimated in histological and immunohisto-
chemical surveys in which little account may be taken of the
long length of the perivascular drainage pathways, the patchy
nature of Aβ deposits and the relative insensitivity of immuno-
histochemistry as a method for detecting Aβ compared with
biochemical techniques [23]. Methods using isolated
cerebral arteries, stained for amyloid, may give better
estimates of the true prevalence and distribution of CAA in
AD [4,27], and a greater understanding of the dynamics and
pathophysiology of perivascular drainage should help to
resolve any current discrepancies in the role of CAA in the
aetiology of AD.
Role of cerebral amyloid angiopathy in the
accumulation of tau in the brain in Alzheimer disease
In addition to the accumulation of insoluble and soluble Aβs
in the brain in AD, hyperphosphorylated tau accumulates as
neurofibrillary tangle (NFT) in neurons and as neuropil threads
and dystrophic neurites in neuronal processes [64].
Explaining how the accumulation of tau relates to the
deposition of Aβ in the brain has presented a challenge for
many years. In transgenic mice that overexpress both APP
and tau, the deposition of Aβ in the brain precedes and
accelerates the accumulation of intracellular tau [65]. Further-
more, a recent study suggests that failure of elimination of tau
from the extracellular spaces of the brain may play a role in
the intracellular accumulation of tau [66]. In AD, tau
inclusions first appear in neurons in the transentorhinal cortex
and then spread to the hippocampal formation and neocortex
[64]. Cognitive impairment ensues as tau inclusions reach the
hippocampus, and neocortical tau inclusions are a hallmark of
the later and more severe stages of AD [64]. Injections of
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Figure 5
Impaired lymphatic drainage of the brain in the pathogenesis of cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD). The schema
outlines a working hypothesis for the failure of perivascular lymphatic drainage of the brain with age and how such a failure contributes to the
pathogenesis of CAA and AD. Aβ, amyloid-beta; ECS, extracellular spaces; ISF, interstitial fluid; NFT, neurofibrillary tangle.fibrillary tau transfer the propensity to form NFT in mice [66],
which suggests that interference with the disposal of tau from
the extracellular spaces when lymphatic drainage pathways
are blocked by CAA may be a factor in the formation and
spread of NFT in the human brain in AD.
Increase of cerebral amyloid angiopathy
following immunotherapy for Alzheimer
disease
Immunisation against Aβ42 prevents the accumulation of
plaques of Aβ in the brains of young transgenic APP mice
and removes insoluble plaques of Aβ from the brains of older
mice [67]. Similar results with the clearance of Aβ have been
observed in the Elan clinical trial of Aβ immunisation in
patients with AD [68]. However, despite the removal of Aβ
plaques from the brain, there is little evidence that this
benefits cognitive function [69].
Figure 6 is a summary of the effects of Aβ42 immunisation on
the brain in AD. In non-immunised patients with AD
(Figure 6a), insoluble Aβ is present in the brain parenchyma as
diffuse plaques and as compact neuritic plaques surrounded
by dystrophic neurites containing hyperphosphorylated tau.
Neuropil threads and neurons containing NFT are also present
in the brains of unimmunised patients. Following immunisation
with Aβ42 (Figure 6b), insoluble Aβ in the plaques is removed
by antibodies and activated microglia and the dystrophic
neurites associated with neuritic plaques disappear [46].
NFTs in neurons and neuropil threads remain [46]. However,
the severity of CAA increases following immunotherapy
(Figure 6b) [46,70], and there is some indication that the level
of soluble Aβ rises in the brains of treated patients [71].
There is an increase in Aβ42 in capillary and artery walls
following immunisation in AD [45,46]. Aβ40 is usually the
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Figure 6
Changes in the brain induced by amyloid-beta (Aβ) immunotherapy. Comparison of frames (a) and (b) shows the major effects of Aβ
immunotherapy upon the brain. There is a decrease in plaques of Aβ and of dystrophic neurites but an increase in the severity of cerebral amyloid
angiopathy (CAA), in microglial activation (for the degradation of Aβ plaques), and in the level of soluble Aβ in the brain parenchyma. Neurofibrillary
tangles (NFTs) and neuropil threads are still present. AD, Alzheimer disease.predominant amyloid in vessel walls and Aβ42 is mainly in the
plaques [23]. Increased amounts of Aβ42 in vessel walls
appear to be the result of removal of the Aβ plaques [45,46],
allowing more Aβ42 to reach drainage channels in capillary
and artery walls, where its further removal is blocked and the
severity of CAA increases [46].
Changes in the white matter of patients treated with
immunotherapy have raised concerns [68,72]. The increased
signal seen in the white matter on T2-weighted magnetic
resonance imaging in many older individuals and in those with
AD [73] and often ascribed to ischaemia is aggravated by
immunotherapy [68]. Failure of fluid drainage from the white
matter along arteries that are severely affected by CAA [27]
may be a factor in the increased white matter changes
following immunisation.
Solving the problem of CAA is obviously a priority for
ensuring the success of immunotherapy for AD and there is
some indication that this may be possible. Although Aβ
immunotherapy in APP mice usually results in an increase in
CAA [70], passive immunisation with antibodies that bind to
the N-terminal portion of Aβ results in a reduction of CAA
[74]. Furthermore, two human cases who survived for 5 years
following immunisation showed extensive clearance of Aβ
from plaques and very little CAA [46]. It is possible that, with
time, CAA will resolve in some immunised patients. The role
of apoE in the elimination of Aβ from the brain is still not fully
established, but the marked accumulation of apoE co-
localising with Aβ in CAA following immunisation suggests
that the elimination of Aβ may be chaperoned by apoE [45].
Conclusions and future directions
Elimination of Aβ from the brain involves enzymic degradation,
its absorption into the blood and drainage of Aβ along
perivascular lymphatic drainage pathways. All of these
mechanisms appear to fail as the brain and cerebral arteries
age. One of the major consequences of this failure is the
obstruction of lymphatic drainage of fluid and solutes from
the brain by CAA that results in the accumulation of insoluble
and soluble Aβs in the brain and probably other metabolites
that would lead to loss of homeostasis of the neuronal
environment. Accumulation of hyperphosphorylated tau in
neurons and failure of neuronal function may ensue from the
loss of homeostasis.
The therapeutic challenge is to ensure adequate elimination
of Aβ from the ageing brain and along ageing cerebral
arteries. Pharmacological intervention to enhance enzymic
degradation of Aβ and absorption of Aβ into the blood is one
obvious direction to take. Resolving the inadequacies of the
ageing lymphatic drainage pathway will entail a greater
understanding of its physiology and how the various elements
such as basement membranes, smooth muscle cells and
perivascular cells interact and how they change with age.
Establishing the role played by apoE in the elimination of Aβ
and harnessing this information for the design of therapies
may help to prevent the accumulation of amyloid in blood
vessel walls and brain in AD.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank Anton Page of the Biomedical Imaging Unit, Southampton
General Hospital, for his help with the illustrations and Delphin Boche
(Clinical Neurosciences, Southampton) for her advice on the manu-
script. This work was supported by the Alzheimer’s Research Trust
(UK).
References
1. Love S, Miners S, Palmer J, Chalmers K, Kehoe P: Insights into
the pathogenesis and pathogenicity of cerebral amyloid
angiopathy. Front Biosci 2009, 14:4778-4792.
2. Esiri MM, Wilcock GK: Cerebral amyloid angiopathy in demen-
tia and old age. J Neurol Neurosurg Psychiat 1986, 49:1221-
1226.
3. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll
JAR, Perry VH, Weller RO: Solutes, but not cells, drain from the
brain parenchyma along basement membranes of capillaries
and arteries. Significance for cerebral amyloid angiopathy and
neuroimmunology. Neuropathol Appl Neurobiol 2008, 34:131-
144.
4. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher
AE: Cerebral amyloid angiopathy: amyloid beta accumulates
in putative interstitial fluid drainage pathways in Alzheimer’s
disease. Am J Pathol 1998, 153:725-733.
5. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO:
Perivascular drainage of amyloid-beta peptides from the brain
and its failure in cerebral amyloid angiopathy and Alzheimer’s
disease. Brain Pathol 2008, 18:253-266.
6. Muthuchamy M, Zawieja D: Molecular regulation of lymphatic
contractility. Ann N Y Acad Sci 2008, 1131:89-99.
7. Weller RO, Djuanda E, Yow HY, Carare RO: Lymphatic drainage
of the brain and the pathophysiology of neurological disease.
Acta Neuropathol 2009, 117:1-14.
8. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO:
Mechanisms to explain the reverse perivascular transport of
solutes out of the brain. J Theor Biol 2006, 238:962-974.
9. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF: Drainage of inter-
stitial fluid from different regions of rat brain. Am J Physiol
1984, 246:F835-844.
10. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A,
Ghiso J: Genetics and molecular pathogenesis of sporadic
and hereditary cerebral amyloid angiopathies. Acta Neu-
ropathol 2009, 118:115-130.
11. Palsdottir A, Snorradottir AO, Thorsteinsson L: Hereditary cys-
tatin C amyloid angiopathy: genetic, clinical, and pathological
aspects. Brain Pathol 2006, 16:55-59.
12. Reilly MM, Staunton H: Peripheral nerve amyloidosis. Brain
Pathol 1996, 6:163-177.
13. Lashley T, Revesz T, Plant G, Bandopadhyay R, Lees AJ, Fran-
gione B, Wood NW, de Silva R, Ghiso J, Rostagno A, Holton JL:
Expression of BRI2 mRNA and protein in normal human brain
and familial British dementia: its relevance to the pathogene-
sis of disease. Neuropathol Appl Neurobiol 2008, 34:492-505.
14. Kovacs GG, Budka H: Molecular pathology of human prion
diseases. Int J Mol Sci 2009, 10:976-999.
15. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse
R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah
E, Oldstone M: Anchorless prion protein results in infectious
amyloid disease without clinical scrapie. Science 2005, 308:
1435-1439
16. Smith EE, Greenberg SM: Beta-amyloid, blood vessels, and
brain function. Stroke 2009, 40:2601-2606.
17. Weller RO, Galea I, Carare RO, Minagar A: Pathophysiology of
the lymphatic drainage of the central nervous system: impli-
cations for pathogenesis and therapy of multiple sclerosis.
Pathophysiology, in press.
Available online http://alzres.com/content/1/2/6
Page 11 of 13
(page number not for citation purposes)18. Scholz W: Studies on the pathology of cerebral blood vessels
II. The nodular degeneration of cerebral arteries and capillar-
ies. (A form of senile vascular disease) [in German]. Zeitschrift
für die gesamte Neurologie und Psychiatrie 1938, 162:694-715.
19. Glenner GG, Wong CW, Quaranta V, Eanes ED: The amyloid
deposits in Alzheimer’s disease: their nature and pathogene-
sis. Appl Pathol 1984, 2:357-369.
20. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD: Vascular
pathology in Alzheimer disease: correlation of cerebral
amyloid angiopathy and arteriosclerosis/lipohyalinosis with
cognitive decline. J Neuropathol Exp Neurol 2003,  62:1287-
1301.
21. Thal DR, Rüb U, Orantes M, Braak H: Phases of A beta-deposi-
tion in the human brain and its relevance for the development
of AD. Neurology 2002, 58:1791-1800.
22. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E: Cerebral
amyloid angiopathy and its relationship to Alzheimer’s
disease. Acta Neuropathol 2008, 115:599-609.
23. Weller RO, Boche D, Nicoll JA: Microvasculature changes and
cerebral amyloid angiopathy in Alzheimer’s disease and their
potential impact on therapy. Acta Neuropathol 2009, 118:87-
102.
24. Wisniewski HM, Wegiel J: Beta-amyloid formation by myocytes
of leptomeningeal vessels. Acta Neuropathol (Berl) 1994, 87:
233-241.
25. Shinkai Y, Yoshimura M, Ito Y, Odaka A, Suzuki N, Yanagisawa K,
Ihara Y: Amyloid beta-proteins 1-40 and 1-42(43) in the
soluble fraction of extra- and intracranial blood vessels. Ann
Neurol 1995, 38:421-428.
26. Domnitz SB, Robbins EM, Hoang AW, Garcia-Alloza M, Hyman
BT, Rebeck GW, Greenberg SM, Bacskai BJ, Frosch MP: Pro-
gression of cerebral amyloid angiopathy in transgenic mouse
models of Alzheimer disease. J Neuropathol Exp Neurol 2005,
64:588-594.
27. Roher AE, Kuo Y-M, Esh C, Knebel C, Weiss N, Kalback W,
Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA: Cor-
tical and leptomeningeal cerebrovascular amyloid and white
matter pathology in Alzheimer’s disease. Mol Med 2003, 9:
112-122.
28. Preston SD, Steart PV, Wilkinson A, Nicoll JAR, Weller RO: Cap-
illary and arterial amyloid angiopathy in Alzheimer’s disease:
defining the perivascular route for the elimination of amyloid
beta from the human brain. Neuropathol Appl Neurobiol 2003,
29:106-117.
29. McCarron MO, Nicoll JA, Stewart J, Ironside JW, Mann DM, Love
S, Graham DI, Dewar D: The apolipoprotein E epsilon2 allele
and the pathological features in cerebral amyloid angiopathy-
related hemorrhage. J Neuropathol Exp Neurol 1999, 58:711-
718.
30. Oshima K, Akiyama H, Tsuchiya K, Kondo H, Haga C, Shimomura
Y, Iseki E, Uchikado H, Kato M, Niizato K, Arai H: Relative paucity
of tau accumulation in the small areas with abundant
Abeta42-positive capillary amyloid angiopathy within a given
cortical region in the brain of patients with Alzheimer pathol-
ogy. Acta Neuropathol (Berl) 2006, 111:510-518.
31. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Tredici KD,
Braak H: Two types of sporadic cerebral amyloid angiopathy. J
Neuropathol Exp Neurol 2002, 61:282-293.
32. Yow HY, Weller RO: A role for cerebrovascular disease in
determining the pattern of beta amyloid deposition in
Alzheimer’s disease. Neuropathol Appl Neurobiol 2002,
28:149.
33. Abbott NJ: Evidence for bulk flow of brain interstitial fluid: sig-
nificance for physiology and pathology. Neurochem Int 2004,
45:545-552.
34. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M,
Wiederhold KH, Abramowski D, Sturchler Pierrat C, Sommer B,
Staufenbiel M, Jucker M: Neuronal overexpression of mutant
amyloid precursor protein results in prominent deposition of
cerebrovascular amyloid. Proc Natl Acad Sci U S A 1999, 96:
14088-14093.
35. Herzig MC, Van Nostrand WE, Jucker M: Mechanism of cerebral
beta-amyloid angiopathy: murine and cellular models. Brain
Pathol 2006, 16:40-54.
36. Nicoll JAR, Yamada M, Frackowiak J, Mazur Kolecka B, Weller
RO:  Cerebral amyloid angiopathy plays a direct role in the
pathogenesis of Alzheimer’s disease. Pro-CAA position state-
ment. Neurobiol Aging 2004, 25:589-597; discussion 603-604.
37. Cserr HF, Harling-Berg CJ, Knopf PM: Drainage of brain extra-
cellular fluid into blood and deep cervical lymph and its
immunological significance. Brain Pathol 1992, 2:269-276.
38. Syková E, Nicholson C: Diffusion in brain extracellular space.
Physiol Rev 2008, 88:1277-1340.
39. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg
S, Beckmann N: Capillary cerebral amyloid angiopathy is asso-
ciated with vessel occlusion and cerebral blood flow distur-
bances. Neurobiol Aging 2008, Mar 20. [Epub ahead of print].
40. Clapham R, O’Sullivan E, Weller RO, Carare RO: Cervical lymph
nodes are found in direct relationship with the carotid arter-
ies. Significance for the lymphatic drainage of the brain. Clin
Anat, in press.
41. Wyss Coray T, Lin C, Sanan DA, Mucke L, Masliah E: Chronic
overproduction of transforming growth factor-beta1 by astro-
cytes promotes Alzheimer’s disease-like microvascular
degeneration in transgenic mice. Am J Pathol 2000, 156:139-
150.
42. Beach TG: Physiologic origins of age-related beta-amyloid
deposition. Neurodegener Dis 2008, 5:143-145.
43. Bell RD, Zlokovic BV: Neurovascular mechanisms and blood-
brain barrier disorder in Alzheimer’s disease. Acta Neuropathol
2009, 118:103-113.
44. Attems J, Jellinger K: Only cerebral capillary amyloid angiopa-
thy correlates with Alzheimer pathology - a pilot study. Acta
Neuropathol (Berl) 2004, 107:83-90.
45. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vla-
chouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D,
Holmes C: Abeta species removal after Abeta42 immuniza-
tion. J Neuropathol Exp Neurol 2006, 65:1040-1048.
46. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM,
Wilkinson D, Holmes C, Nicoll JA: Consequence of Abeta
immunization on the vasculature of human Alzheimer’s
disease brain. Brain 2008, 131:3299-3310.
47. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S,
Kehoe PG: Decreased expression and activity of neprilysin in
Alzheimer disease are associated with cerebral amyloid
angiopathy. J Neuropathol Exp Neurol 2006, 65:1012-1021.
48. Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A,
Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ:
Loss of neprilysin function promotes amyloid plaque forma-
tion and causes cerebral amyloid angiopathy. Am J Pathol
2007, 171:241-251.
49. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione
B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV:
Clearance of Alzheimer’s amyloid-beta(1-40) peptide from
brain by LDL receptor-related protein-1 at the blood-brain
barrier. J Clin Invest 2000, 106:1489-1499.
50. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane
R, Zlokovic BV: Transport pathways for clearance of human
Alzheimer’s amyloid beta-peptide and apolipoproteins E and J
in the mouse central nervous system. J Cereb Blood Flow
Metab 2007, 27:909-918.
51. Hawkes CA, McLaurin J: Selective targeting of perivascular
macrophages for clearance of beta-amyloid in cerebral
amyloid angiopathy. Proc Natl Acad Sci U S A 2009,  106:
1261-1266.
52. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA,
Frosch MP, Greenberg SM: The cerebral beta-amyloid
angiopathies: hereditary and sporadic. Brain Pathol 2006, 16:
30-39.
53. Rosand J, Muzikansky A, Kumar A, Wisco JJ, Smith EE, Betensky
RA, Greenberg SM: Spatial clustering of hemorrhages in prob-
able cerebral amyloid angiopathy. Ann Neurol 2005, 58:459-
462.
54. Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, Ellison
D, Hilton DA, Williams TL, MacKenzie JM, Xuereb JH, Love S:
Abeta-related angiitis: primary angiitis of the central nervous
system associated with cerebral amyloid angiopathy. Brain
2005, 128:500-515.
55. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J,
Greenberg SM: Impaired visual evoked flow velocity response
in cerebral amyloid angiopathy. Neurology 2008,  71:1424-
1430.
56. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S,
Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P,
Alzheimer’s Research & Therapy    Vol 1 No 2 Weller et al.
Page 12 of 13
(page number not for citation purposes)Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM,
Ghiso J, Staufenbiel M, Walker LC, Jucker M: Exogenous induc-
tion of cerebral beta-amyloidogenesis is governed by agent
and host. Science 2006, 313:1781-1784.
57. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E,
Pfeifer M, Boncristiano S, Matthews PM, Mercken M, Abramowski
D, Staufenbiel M, Jucker M: Extracellular amyloid formation and
associated pathology in neural grafts. Nat Neurosci 2003, 6:
328-330.
58. Mueggler T, Rausch M, Meyer-Luehmann M, Staufenbiel M, Jucker
M, Rudin M: Restricted diffusion in the brain of transgenic
mice with cerebral amyloidosis. Eur J Neurosci 2004, 20:811-
817.
59. Sykova E, Vorisek I, Antonova T, Mazel T, Meyer-Luehmann M,
Jucker M, Hajek M, Ort M, Bures J: Changes in extracellular
space size and geometry in APP23 transgenic mice: a model
of Alzheimer’s disease. Proc Natl Acad Sci U S A 2005, 102:
479-484.
60. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR,
Weller RO, Roher AE: Elevated A beta and apolipoprotein E in
A betaPP transgenic mice and its relationship to amyloid
accumulation in Alzheimer’s disease. Mol Med 2000, 6:430-
439.
61. CFAS NGoM: Pathological correlates of late-onset dementia
in a multicentre, community-based population in England and
Wales. Lancet 2001, 357:169-175.
62. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T,
Kurth JH, Rydel RE, Rogers J: Soluble amyloid beta peptide
concentration as a predictor of synaptic change in
Alzheimer’s disease. Am J Pathol 1999, 155:853-862.
63. Tomic JL, Pensalfini A, Head E, Glabe CG: Soluble fibrillar
oligomer levels are elevated in Alzheimer’s disease brain and
correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:
352-358.
64. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K:
Staging of Alzheimer disease-associated neurofibrillary
pathology using paraffin sections and immunocytochemistry.
Acta Neuropathol 2006, 112:389-404.
65. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM:
Amyloid deposition precedes tangle formation in a triple
transgenic model of Alzheimer’s disease. Neurobiol Aging
2003, 24:1063-1070.
66. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S,
Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker
M, Goedert M, Tolnay M: Transmission and spreading of
tauopathy in transgenic mouse brain. Nat Cell Biol 2009, 11:
909-913.
67. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T,
Hu K, Huang J, Johnson Wood K, Khan K, Kholodenko D, Lee M,
Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G,
Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T,
Games D, Seubert P: Immunization with amyloid-beta attenu-
ates Alzheimer-disease-like pathology in the PDAPP mouse.
Nature 1999, 400:173-177.
68. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller
RO:  Neuropathology of human Alzheimer disease after
immunization with amyloid-beta peptide: a case report. Nat
Med 2003, 9:448-452.
69. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V,
Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll
JA: Long-term effects of Abeta42 immunisation in Alzheimer’s
disease: follow-up of a randomised, placebo-controlled phase
I trial. Lancet 2008, 372:216-223.
70. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ,
Gordon MN, Morgan D: Passive immunotherapy against Abeta
in aged APP-transgenic mice reverses cognitive deficits and
depletes parenchymal amyloid deposits in spite of increased
vascular amyloid and microhemorrhage. J Neuroinflammation
2004, 1:24.
71. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD,
Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel
AJ, Beach TG, Castaño EM, Roher AE: Amyloid-beta peptide
remnants in AN-1792-immunized Alzheimer’s disease
patients: a biochemical analysis. Am J Pathol 2006, 169:1048-
1063.
72. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby
LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada
M, Frank A, Hock C: Subacute meningoencephalitis in a
subset of patients with AD after Abeta42 immunization. Neu-
rology 2003, 61:46-54.
73. Pantoni L: Leukoaraiosis: from an ancient term to an actual
marker of poor prognosis. Stroke 2008, 39:1401-1403.
74. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill
D, Basi G, Schenk D, Seubert P, Games D: Immunotherapy
reduces vascular amyloid-beta in PDAPP mice. J Neurosci
2008, 28:6787-6793.
Available online http://alzres.com/content/1/2/6
Page 13 of 13
(page number not for citation purposes)